MeiraGTx chief scientific officer Naylor sells $294,291 in shares

Chief Scientific Officer of MeiraGTx, Stuart Naylor, divested 27,659 ordinary shares on October 6, 2026, according to disclosed transactions. The sale generated a total of $294,291, with share prices fluctuating between $10.53 and $10.88. The trades were carried out in compliance with a Rule 10b5-1 trading plan initiated by Naylor on December 9, 2025.

As a result of these sales, Naylor now directly owns 613,187 shares of MeiraGTx. Currently, the company's stock price stands at $10.69, representing a 34% increase year-to-date, and MGTX boasts a market capitalization of $1.03 billion. Financial analysts have noted that MGTX is trading close to its fair value, and the company has demonstrated profitability over the past year.

ProTips and comprehensive financial data are available on the InvestingPro platform. MeiraGTx has also drawn attention from analysts, with mixed opinions. Goldman Sachs assigned a Neutral rating with a price target of $16.00, acknowledging the company's work on gene therapies for various conditions. Conversely, Raymond James maintained a Strong Buy rating, citing positive data from a rival company's gene therapy as a potential boost for MeiraGTx's product, bota-vec.

Notably, MeiraGTx has recently reacquired the rights to bota-vec from Johnson & Johnson after a trial failed to meet its primary endpoint. These developments suggest a blend of cautious optimism and strategic shifts for the company. This report was AI-generated and reviewed by an editor.